Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Reduce” by Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received a consensus recommendation of “Reduce” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $28.00.

Several brokerages have recently commented on FMS. Erste Group Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, January 27th. Bank of America lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Finally, UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock worth $176,000 after buying an additional 699 shares in the last quarter. ABC Arbitrage SA raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% during the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after acquiring an additional 229,589 shares in the last quarter. QRG Capital Management Inc. boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 4.4% during the 4th quarter. QRG Capital Management Inc. now owns 67,771 shares of the company’s stock valued at $1,614,000 after acquiring an additional 2,869 shares during the last quarter. Advisors Preferred LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at approximately $227,000. Finally, Ping Capital Management Inc. bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth $238,000. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

FMS opened at $24.03 on Wednesday. The company has a 50 day simple moving average of $23.15 and a two-hundred day simple moving average of $24.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The firm has a market cap of $13.93 billion, a P/E ratio of 17.54, a PEG ratio of 0.75 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.